Miao Yajun, Fan Yingrui, Zhang Liang, Ma Tingting, Li Rong
Department of Oncology, the First People's Hospital of Nantong. No.6, Haierxiang North Road, 226001 Nantong, Jiangsu Province, China.
Department of Oncology, TaiKang XianLin Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. No.188, Lingshan North Road, Qixia District, 210046 Nanjing, Jiangsu Province, China.
Cell Mol Biol (Noisy-le-grand). 2019 Jul 31;65(6):64-72.
Breast cancer is a malignant tumor that occurs in the glandular epithelial tissues of the breast. It is one of the most common malignant tumors in women. This study was aimed at investigating the role of cell-free DNA (cfDNA) as a potential biomarker for breast cancer diagnosis. Patients with primary breast cancer (n =110) were enrolled in the experimental group, 95 patients with benign breast tumors were in control group 1, while 90 healthy volunteers were in control group 2. Quantitative PCR was used to determine cfDNA concentration and integrity in each group. The cfDNA levels in different groups and their relationship with clinical features of breast cancer patients were analyzed. Receiver operational curves were established to analyze sensitivity and specificity of cfDNA concentration, cfDNA integrity, CEA, CA125 and CA15-3. The cfDNA concentration and cfDNA integrity of the experimental group were significantly higher than those of control groups 1 and 2. The cfDNA concentration and integrity in plasma of experimental group after chemotherapy were significantly lower than those before chemotherapy. While CEA and CA15-3 expressions were significantly correlated with cfDNA concentration, CA125 expression was significantly correlated with cfDNA integrity. Results from ROC curve analysis showed that the sensitivity and specificity of cfDNA concentration and integrity were higher than those of traditional tumor biomarkers. These results indicate that cfDNA concentration and integrity are significantly higher in primary breast cancer patients than in benign breast tumor patients and healthy people. Thus, cfDNA may serve as a potential biomarker of breast cancer.
乳腺癌是发生于乳腺腺上皮组织的恶性肿瘤。它是女性最常见的恶性肿瘤之一。本研究旨在探讨游离DNA（cfDNA）作为乳腺癌诊断潜在生物标志物的作用。原发性乳腺癌患者（n = 110）纳入实验组，95例乳腺良性肿瘤患者为对照组1，90例健康志愿者为对照组2。采用定量PCR测定每组cfDNA的浓度和完整性。分析不同组cfDNA水平及其与乳腺癌患者临床特征的关系。绘制受试者工作曲线，分析cfDNA浓度、cfDNA完整性、癌胚抗原（CEA）、糖类抗原125（CA125）和糖类抗原15-3（CA15-3）的敏感性和特异性。实验组cfDNA浓度和cfDNA完整性显著高于对照组1和对照组2。实验组化疗后血浆中cfDNA浓度和完整性显著低于化疗前。CEA和CA15-3表达与cfDNA浓度显著相关，CA125表达与cfDNA完整性显著相关。ROC曲线分析结果显示，cfDNA浓度和完整性的敏感性和特异性高于传统肿瘤生物标志物。这些结果表明，原发性乳腺癌患者cfDNA浓度和完整性显著高于乳腺良性肿瘤患者和健康人。因此，cfDNA可能作为乳腺癌的潜在生物标志物。
